Literature DB >> 24123296

Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting.

Alphonse E Sirica1, Gregory J Gores.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24123296      PMCID： PMC3975806          DOI： 10.1002/hep.26762

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  37 in total

1.  Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma.

Authors:  Horlad Hasita; Yoshihiro Komohara; Hirohisa Okabe; Toshiro Masuda; Koji Ohnishi; Xiao F Lei; Toru Beppu; Hideo Baba; Motohiro Takeya
Journal:  Cancer Sci       Date:  2010-05-12       Impact factor: 6.716

2.  Reduction of periductal fibrosis in liver fluke-infected hamsters after long-term curcumin treatment.

Authors:  Somchai Pinlaor; Suksanti Prakobwong; Yusuke Hiraku; Porntip Pinlaor; Umawadee Laothong; Puangrat Yongvanit
Journal:  Eur J Pharmacol       Date:  2010-04-24       Impact factor: 4.432

3.  Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate.

Authors:  Youngchul Kim; Maria I Fiel; Efsevia Albanis; Hsin I Chou; Weijia Zhang; Gregory Khitrov; Scott L Friedman
Journal:  Liver Int       Date:  2012-04-16       Impact factor: 5.828

4.  Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis.

Authors:  Suksanti Prakobwong; Jarinya Khoontawad; Puangrat Yongvanit; Chawalit Pairojkul; Yusuke Hiraku; Paiboon Sithithaworn; Porntip Pinlaor; Bharat B Aggarwal; Somchai Pinlaor
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.396

5.  Desmoplasia: a response or a niche?

Authors:  Yves A DeClerck
Journal:  Cancer Discov       Date:  2012-09       Impact factor: 39.397

6.  Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes.

Authors:  Raghu Kadaba; Hanna Birke; Jun Wang; Steven Hooper; Claudia D Andl; Francesco Di Maggio; Erdinc Soylu; Mohammed Ghallab; Daniel Bor; Fieke Em Froeling; Satyajit Bhattacharya; Anil K Rustgi; Erik Sahai; Claude Chelala; Peter Sasieni; Hemant M Kocher
Journal:  J Pathol       Date:  2013-03-21       Impact factor: 7.996

7.  Activated hepatic stellate cells mediate the differentiation of macrophages.

Authors:  Jonathan Chang; Tadakazu Hisamatsu; Katsuyoshi Shimamura; Kazuaki Yoneno; Masayuki Adachi; Hiroshi Naruse; Toru Igarashi; Hajime Higuchi; Katsuyoshi Matsuoka; Mina T Kitazume; Setsu Ando; Nobuhiko Kamada; Takanori Kanai; Toshifumi Hibi
Journal:  Hepatol Res       Date:  2012-10-29       Impact factor: 4.288

8.  Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma.

Authors:  Hirohisa Okabe; Toru Beppu; Hiromitsu Hayashi; Kei Horino; Toshiro Masuda; Hiroyuki Komori; Shinji Ishikawa; Masayuki Watanabe; Hiroshi Takamori; Ken-ichi Iyama; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2009-06-23       Impact factor: 5.344

9.  Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor.

Authors:  Audrey Clapéron; Martine Mergey; Lynda Aoudjehane; Thanh Huong Nguyen Ho-Bouldoires; Dominique Wendum; Aurélie Prignon; Fatiha Merabtene; Delphine Firrincieli; Christèle Desbois-Mouthon; Olivier Scatton; Filomena Conti; Chantal Housset; Laura Fouassier
Journal:  Hepatology       Date:  2013-10-25       Impact factor: 17.425

10.  Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats.

Authors:  Hong Ling; Eric Roux; Donna Hempel; Jingzang Tao; Mandy Smith; Scott Lonning; Anna Zuk; Cynthia Arbeeny; Steve Ledbetter
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240
View more
  54 in total

Review 1.  Cholangiocarcinoma: molecular pathways and therapeutic opportunities.

Authors:  Sumera Rizvi; Mitesh J Borad; Tushar Patel; Gregory J Gores
Journal:  Semin Liver Dis       Date:  2014-11-04       Impact factor: 6.115

Review 2.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

3.  Transforming Growth Factors α and β Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model.

Authors:  Miguel Á Manzanares; Akihiro Usui; Deanna J Campbell; Catherine I Dumur; Gabrielle T Maldonado; Michel Fausther; Jonathan A Dranoff; Alphonse E Sirica
Journal:  Am J Pathol       Date:  2017-03-15       Impact factor: 4.307

Review 4.  Liver transplantation in the management of perihilar cholangiocarcinoma.

Authors:  Aliya F Gulamhusein; William Sanchez
Journal:  Hepat Oncol       Date:  2015-11-06

5.  Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.

Authors:  Chirag Nepal; Colm J O'Rourke; Douglas V N P Oliveira; Andrzej Taranta; Steven Shema; Prson Gautam; Julien Calderaro; Andrew Barbour; Chiara Raggi; Krister Wennerberg; Xin W Wang; Anja Lautem; Lewis R Roberts; Jesper B Andersen
Journal:  Hepatology       Date:  2018-06-12       Impact factor: 17.425

Review 6.  Current diagnostic and management options in perihilar cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Digestion       Date:  2014-05-22       Impact factor: 3.216

Review 7.  Targeted therapy in biliary tract cancers-current limitations and potentials in the future.

Authors:  Selley Sahu; Weijing Sun
Journal:  J Gastrointest Oncol       Date:  2017-04

Review 8.  Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications.

Authors:  Alphonse E Sirica; Jorge A Almenara; Chao Li
Journal:  Exp Mol Pathol       Date:  2014-10-28       Impact factor: 3.362

9.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

10.  SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model.

Authors:  Meng Xu; Jingxiao Wang; Zhong Xu; Rong Li; Pan Wang; Runze Shang; Antonio Cigliano; Silvia Ribback; Antonio Solinas; Giovanni Mario Pes; Katja Evert; Haichuan Wang; Xinhua Song; Shu Zhang; Li Che; Rosa Maria Pascale; Diego Francesco Calvisi; Qingguang Liu; Xin Chen
Journal:  Cancer Res       Date:  2019-08-05       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.